Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph 1/1b, CPI-444 as Single Agent in Combination with Atezolizumab Therapy in Pti w/ Incurable Ca

Protocol: OSU-16051

Full Title

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab Therapy in Patients with Selected Incurable Cancers

Lung Cancers Melanoma Skin Cancers Kidney Cancer Genitourinary Cancers Breast Cancer Colon Cancer Gastrointestinal Cancers Rectal Cancer Bladder Cancer